interferon in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Davoudi-Monfared, 2020 0.30 [0.11; 0.83]
Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
0.59 [0.13 ; 2.76 ] Davoudi-Monfared, 2020, Pandit, 2021, Shashi Bhushan, 2021 3 27% 370 serious not evaluable deathsdetailed results Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
Esquivel-Moynelo, 2020 1.10 [0.02; 57.31]
Fu, 2020 1.00 [0.02; 51.66]
Pandit, 2021 0.95 [0.02; 50.33]
Rahmani, 2020 0.29 [0.05; 1.56]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
0.43 [0.25 ; 0.76 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Esquivel-Moynelo, 2020, Fu, 2020, Pandit, 2021, Rahmani, 2020, Shashi Bhushan, 2021 8 0% 670 moderate serious deaths (time to event analysis only)detailed results Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
0.38 [0.16 ; 0.87 ] Davoudi-Monfared, 2020 1 0% 92 NA not evaluable clinical deteriorationdetailed results Esquivel-Moynelo, 2020 2.29 [0.20; 26.58]
2.29 [0.20 ; 26.58 ] Esquivel-Moynelo, 2020 1 0% 63 NA not evaluable clinical improvementdetailed results Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
1.29 [0.69 ; 2.42 ] Darazam (COVIFERON Interferon beta-1a), 2021, Davoudi-Monfared, 2020, Shashi Bhushan, 2021 3 48% 363 moderate not evaluable clinical improvement (14-day)detailed results Pandit, 2021 8.77 [0.94; 81.67]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
2.03 [0.17 ; 24.32 ] Pandit, 2021, Shashi Bhushan, 2021 2 75% 281 moderate not evaluable clinical improvement (7-day)detailed results Shashi Bhushan, 2021 1.91 [1.03; 3.53]
1.91 [1.03 ; 3.53 ] Shashi Bhushan, 2021 1 0% 222 NA not evaluable clinical improvement (time to event analysis only)detailed results Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Rahmani, 2020 3.41 [1.33; 8.73]
1.73 [1.05 ; 2.86 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Rahmani, 2020 4 45% 227 moderate not evaluable hospital dischargedetailed results Davoudi-Monfared, 2020 1.96 [0.76; 5.03]
Rahmani, 2020 3.44 [0.64; 18.49]
2.24 [0.99 ; 5.10 ] Davoudi-Monfared, 2020, Rahmani, 2020 2 0% 147 serious not evaluable mechanical ventilationdetailed results Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Davoudi-Monfared, 2020 0.72 [0.29; 1.76]
Rahmani, 2020 0.29 [0.05; 1.56]
0.74 [0.41 ; 1.34 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Rahmani, 2020 4 0% 227 moderate not evaluable viral clearance detailed results Esquivel-Moynelo, 2020 3.26 [1.53; 6.95]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
2.89 [1.81 ; 4.62 ] Esquivel-Moynelo, 2020, Pandit, 2021, Shashi Bhushan, 2021 3 0% 344 moderate not evaluable viral clearance (time to event analysis only)detailed results Esquivel-Moynelo, 2020 3.26 [1.53; 6.95]
3.26 [1.53 ; 6.95 ] Esquivel-Moynelo, 2020 1 0% 63 NA not evaluable viral clearance by day 14detailed results Esquivel-Moynelo, 2020 5.90 [0.28; 122.94]
Pandit, 2021 10.23 [1.12; 93.35]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
0.55 [0.00 ; 227.28 ] Esquivel-Moynelo, 2020, Pandit, 2021, Shashi Bhushan, 2021 3 96% 1,422 moderate not evaluable viral clearance by day 7detailed results Esquivel-Moynelo, 2020 3.09 [1.04; 9.17]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
2.78 [1.65 ; 4.68 ] Esquivel-Moynelo, 2020, Pandit, 2021, Shashi Bhushan, 2021 3 0% 344 moderate not evaluable ICU admissiondetailed results Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Rahmani, 2020 0.37 [0.14; 1.00]
0.49 [0.24 ; 1.00 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 2020 3 0% 146 moderate not evaluable off oxygenationdetailed results Davoudi-Monfared, 2020 8.57 [1.43; 51.36]
8.57 [1.43 ; 51.36 ] Davoudi-Monfared, 2020 1 0% 32 NA not evaluable serious adverse eventsdetailed results Pandit, 2021 0.95 [0.02; 50.33]
0.95 [0.02 ; 50.33 ] Pandit, 2021 1 0% 39 NA not evaluable superinfectiondetailed results Davoudi-Monfared, 2020 2.41 [0.75; 7.73]
Rahmani, 2020 0.18 [0.02; 1.59]
0.77 [0.06 ; 9.89 ] Davoudi-Monfared, 2020, Rahmani, 2020 2 76% 147 serious not evaluable adverse eventsdetailed results Esquivel-Moynelo, 2020 1.33 [0.45; 3.92]
Pandit, 2021 1.68 [0.47; 5.97]
1.47 [0.65 ; 3.34 ] Esquivel-Moynelo, 2020, Pandit, 2021 2 0% 102 serious not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-02 22:13 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 517,881,904,882,897,896,899,1235,898,687,740,883,947
- roots T: 290
